Lead Sponsor

Eli Lilly and Company

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

•Present with GPP or EP based on an investigator-confirmed diagnosis and meet the associated criteria
•* GPP: Meet the criteria for GPP set by Ministry of Health, Labour and Welfare (MHLW) at screening and baseline regardless of IL-36 mutation status.
•* EP: Diagnosed to have BSA ≥80% involvement (with inflammatory erythema) at screening and baseline.
•Candidates for phototherapy and/or systemic therapy
•Men must agree to use a reliable method of birth control during the study
•Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

•History of drug-induced psoriasis
•Concurrent or recent use of any biologic agent
•Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
•Have previously received ixekizumab
•Serious disorder or illness other than psoriasis
•Serious infection within the last 12 weeks
•Breastfeeding or nursing (lactating) women

Related studies

NCT06100991 · Generalized Pustular Psoriasis

NCT06477536 · Generalized Pustular Psoriasis

NCT06323356 · Generalized Pustular Psoriasis, Erythrodermic Psoriasis

NCT07448428 · Generalized Pustular Psoriasis, Generalized Pustular Psoriasis (GPP)

NCT06886009 · Generalized Pustular Psoriasis

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis